IT1254280B - Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson - Google Patents

Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson

Info

Publication number
IT1254280B
IT1254280B ITMI920591A ITMI920591A IT1254280B IT 1254280 B IT1254280 B IT 1254280B IT MI920591 A ITMI920591 A IT MI920591A IT MI920591 A ITMI920591 A IT MI920591A IT 1254280 B IT1254280 B IT 1254280B
Authority
IT
Italy
Prior art keywords
treatment
pharmaceutical compositions
compositions including
parkinson disease
derivatives suitable
Prior art date
Application number
ITMI920591A
Other languages
English (en)
Inventor
Gino Toffano
Aurelio Romeo
Original Assignee
Fidia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Spa filed Critical Fidia Spa
Publication of ITMI920591A0 publication Critical patent/ITMI920591A0/it
Priority to ITMI920591A priority Critical patent/IT1254280B/it
Priority to PCT/EP1993/000571 priority patent/WO1993017691A2/en
Priority to EP96116051A priority patent/EP0770389B1/en
Priority to AU37477/93A priority patent/AU3747793A/en
Priority to JP5515350A priority patent/JP2872809B2/ja
Priority to ES96116051T priority patent/ES2161953T3/es
Priority to DE69330842T priority patent/DE69330842T2/de
Priority to EP93906509A priority patent/EP0630250A1/en
Priority to AT96116051T priority patent/ATE206053T1/de
Publication of ITMI920591A1 publication Critical patent/ITMI920591A1/it
Priority to US08/304,391 priority patent/US6620792B1/en
Application granted granted Critical
Publication of IT1254280B publication Critical patent/IT1254280B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invenzione si riferisce a composizioni farmaceutiche comprendenti monosialoganglioside GM1, o un suo derivato scelto fra l'estere interno AGF2 e l'estere metilico AGF4, atte al trattamento della patologia parkinsoniana.Un ulteriore oggetto della presente invenzione è una terapia associata per il trattamento della malattia di Parkinson, rappresentata dalla somministrazione di detti composti e di farmaci noti attivi nel sopraindicato trattamento, ed in modo preferenziale la terapia associata con L-Dopa.
ITMI920591A 1992-03-13 1992-03-13 Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson IT1254280B (it)

Priority Applications (10)

Application Number Priority Date Filing Date Title
ITMI920591A IT1254280B (it) 1992-03-13 1992-03-13 Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson
JP5515350A JP2872809B2 (ja) 1992-03-13 1993-03-12 モノシアロガングリオシドｇｍ▲下１▼またはその誘導体を含有する，パーキンソン病の治療に適する医薬組成物
EP96116051A EP0770389B1 (en) 1992-03-13 1993-03-12 Use of monosialoganglioside GM1 or N-dichloro-acetyl-lyso-GM1 for preventing or reversing neuronal degeneration induced by a long term treatment with L-DOPA in the therapy of Parkinson's disease
AU37477/93A AU3747793A (en) 1992-03-13 1993-03-12 Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson's disease
PCT/EP1993/000571 WO1993017691A2 (en) 1992-03-13 1993-03-12 Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson's disease
ES96116051T ES2161953T3 (es) 1992-03-13 1993-03-12 Utilizacion del monosialogangliosido gm1 o del n-dicloroacetil-liso-gm1 para prevenir o invertir la degeneracion neuronal inducida por un tratamiento de larga duracion con l-dopa en la terapia de la enfermedad de parkinson.
DE69330842T DE69330842T2 (de) 1992-03-13 1993-03-12 Verwendung von Monosialogangliosid GMl oder von N-Dichlor-Acetyl-lyso-GMl zur Vorbeugung oder zur Umkehrung der von einer Langzeitbehandlung mit L-DOPA bei der Therapie von Morbus Parkinson induzierten neuronale Degeneration
EP93906509A EP0630250A1 (en) 1992-03-13 1993-03-12 Pharmaceutical compositions containing monosialoganglioside gm 1? or a derivative thereof suitable for the treatment of parkinson's disease
AT96116051T ATE206053T1 (de) 1992-03-13 1993-03-12 Verwendung von monosialogangliosid gml oder von n-dichlor-acetyl-lyso-gml zur vorbeugung oder zur umkehrung der von einer langzeitbehandlung mit l- dopa bei der therapie von morbus parkinson induzierten neuronale degeneration
US08/304,391 US6620792B1 (en) 1992-03-13 1994-09-12 Pharmaceutical compositions containing monosialoganglioside GM1 or derivative thereof suitable for the treatment of parkinson's disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI920591A IT1254280B (it) 1992-03-13 1992-03-13 Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson

Publications (3)

Publication Number Publication Date
ITMI920591A0 ITMI920591A0 (it) 1992-03-13
ITMI920591A1 ITMI920591A1 (it) 1993-09-13
IT1254280B true IT1254280B (it) 1995-09-14

Family

ID=11362423

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI920591A IT1254280B (it) 1992-03-13 1992-03-13 Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson

Country Status (8)

Country Link
US (1) US6620792B1 (it)
EP (2) EP0630250A1 (it)
JP (1) JP2872809B2 (it)
AT (1) ATE206053T1 (it)
DE (1) DE69330842T2 (it)
ES (1) ES2161953T3 (it)
IT (1) IT1254280B (it)
WO (1) WO1993017691A2 (it)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1259176B (it) * 1992-10-23 1996-03-11 Fidia Spa Composizioni farmaceutiche comprendenti monosialoganglioside gm1 (o suo derivato) e fattore neuronotrofico ciliare (cntf) atte al trattamento di patologie del sistema nervoso
JP2005527467A (ja) * 2001-08-29 2005-09-15 ネオーズ テクノロジーズ， インコーポレイテッド 新規な合成ガングリオシド誘導体およびその組成物
EP1367395A1 (de) 2002-05-02 2003-12-03 B.R.A.H.M.S Aktiengesellschaft Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern
EP1358910A1 (de) * 2002-05-02 2003-11-05 B.R.A.H.M.S Aktiengesellschaft Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen
US7943750B2 (en) * 2007-06-18 2011-05-17 Laboratoire Medidom S.A. Process for obtaining pure monosialoganglioside GM1 for medical use
CN101732331B (zh) * 2008-11-20 2012-05-23 北京四环制药有限公司 一种单唾液酸四己糖神经节苷脂钠与谷氨酸的组合物
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
CN104490837A (zh) * 2014-12-30 2015-04-08 哈尔滨医科大学科技开发总公司 单唾液酸四己糖神经节苷脂钠的口服制剂
RU2632710C2 (ru) * 2016-03-31 2017-10-09 Лонг Шенг Фарма Лимитед Способ получения натрий моносиалового ганглиозида и нейропротекторное средство на его основе
CN108815131B (zh) * 2018-09-11 2021-01-01 四川奇格曼药业有限公司 一种神经节苷脂缓释片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1199116B (it) * 1984-07-03 1988-12-30 Fidia Farmaceutici Derivati di gangliosidi
IT1208751B (it) * 1986-06-30 1989-07-10 Fidia Farmaceutici Possibile uso dei gangliosidi esogeni in malattie tumorali come fattore protettivo contro la neurotossicita' da farmaci antitumorali
IT1235161B (it) * 1988-12-02 1992-06-22 Fidia Farmaceutici Derivati di lisogangliosidi
IT1249034B (it) * 1990-06-29 1995-02-11 Fidia Spa Impiego del monosialoganglioside gm1 e del suo derivato estere interno per impedire l'instaurarsi della tolleranza nell'uomo all'effetto analgesico della morfina e analoghi
IT1253832B (it) * 1991-08-01 1995-08-29 Fidia Spa Derivati di gangliosidi

Also Published As

Publication number Publication date
DE69330842D1 (de) 2001-10-31
ES2161953T3 (es) 2001-12-16
WO1993017691A2 (en) 1993-09-16
JP2872809B2 (ja) 1999-03-24
ITMI920591A0 (it) 1992-03-13
EP0630250A1 (en) 1994-12-28
EP0770389B1 (en) 2001-09-26
ATE206053T1 (de) 2001-10-15
JPH07508258A (ja) 1995-09-14
DE69330842T2 (de) 2002-04-04
EP0770389A1 (en) 1997-05-02
ITMI920591A1 (it) 1993-09-13
WO1993017691A3 (en) 1993-11-11
US6620792B1 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
NO920740D0 (no) Doseringsform for oral administrering av hypoglykemisk glipizid
AU1358695A (en) Nasal administration
EP1014996A4 (en) SACCHARIDE COMPOSITIONS AND METHODS FOR SPECIFIC TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSIS
NZ312715A (en) Novel camptothecin analogues, preparation methods therefor, use thereof as drugs, and pharmaceutical compositions containing said analogues
HK1025915A1 (en) Method of treating dry eye disease with purinergicreceptor agonist.
ES2052717T3 (es) Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
EP1020179A4 (en) PEPTIDE DERIVATIVES OR THEIR PHARMACEUTICAL ACCEPTABLE SALTS, METHOD FOR THE PRODUCTION THEREOF, USE OF THESE DERIVATIVES AND MEDICINAL PRODUCTS
IT1254280B (it) Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson
DK160129C (da) Farmaceutisk praeparat indeholdende en gangliosidforbindelse, et indre ester-gangliosidderivat eller blandinger deraf
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
RU95105973A (ru) Способ снижения тяжести токсоплазмоза, фармацевтическая композиция, применение производных рифамицина для получения лекарственных препаратов для лечения токсоплазмоза
CA2126118A1 (en) 5-Amino-8-Methyl-7-Pyrrolidinylquinoline-3-Carboxylic Acid Derivative
WO1990014831A3 (en) 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition
KR900012881A (ko) 2,3,23-트리하이드록시-우르스-12-엔 및 이의 유도체 이의 제조방법 및 이의 용도
FI104071B1 (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 2,5-dihydro-2,5-diokso-1H-bents[b]atsepiinijohdannaisten valmistamiseksi
ATE69381T1 (de) Anwendung exogener ganglioside zur herstellung eines arzneimittels zur anwendung bei tumorkrankheiten als schutzmittel gegen die toxizitaet tumorhemmender arzneimittel.
DE3175733D1 (en) An orally administered drug form comprising a glycosidic antibiotic and an adjuvant
PH15640A (en) A method for the treatment of pyrexia due to the accentuation of central nerve by administering a derivative of o-aminobenzoic acid
KR950008502A (ko) 3-또는4-클리코실옥시벤조피란 유도체 및 활성 성분으로서 이를 함유하는 알러지치료제
EP0180608B1 (en) 2,3-diamino-2,3-didesoxyhexose derivatives, processes for their preparation and their use
CA2200516A1 (en) Benzopyran derivative and method for treating heart disease using said benzopyran derivative
FR2387035A1 (fr) Nouveau medicament destine notamment au traitement des troubles fonctionnels cerebraux
Devlin et al. Intraocular Penetration of Topical Clindamycin in Rabbits: II. Clindamycin Phosphate